ClinicalTrials.gg

Program

TQB3117

A development code. Also written as “TQB3117 tablets”.

In Sino Biopharmaceutical's pipeline, ATM抑制剂. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 1, since May 13, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since May 13, 2024May 13, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3117, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2024First study: phase 1 study in Advanced Malignant CancerFirst studyNCT06415903 · 59 planned · China

TargetBeta

“ATM抑制剂”the company's pipeline, read by Claude · source

Other programs on ATM

ProgramCompanyFurthest phaseStudies
ATM Inhibitor SYH2051ruleCSPC Pharmaceutical Groupphase 23
AZD1390AstraZenecaphase 13

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06415903Advanced Malignant Cancer · China1Not yet recruitingJun 202559

How it is read

Names in the registry

  • “TQB3117 tablets”, 1 entry

Codes read as this program: TQB3117.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.